Clare specialises in corporate and securities law, with a particular focus on equity capital markets and venture capital.
She has experience in cross-border and domestic corporate transactions including advising on equity fundraisings, private financing and investment transactions, regulated and private M&A, securities regulatory and ASX compliance issues, ESOPs and other general corporate matters.
She regularly acts for companies and investors in the healthcare, medical device and biotechnology sector, as well as the technology industry more broadly. Clare also regularly represents early and growth stage companies and venture capital firms that invest in them.
Clare also has significant experience advising US clients doing business in Australia and Australian clients doing business in the US, including having acted for a number of US companies listed on ASX.
Acting for EBR on its IPO and ASX-listing (2021).
Advised Laybuy Group Holdings Limited on its $80M IPO and ASX-listing in 2020, and its placement and SPP in 2021.
Advised Blackmores Limited on its fully underwritten institutional $92 million placement and $49 million share purchase plan.
Advised on its IPO and ASX listing in 2019 and follow-on capital raisings in 2020 and 2021.
Advised on its non-renounceable entitlement offer in 2020 and placement and SPP in 2021..
Advised on Series C financing in 2020 and 2021, and Series D financing in 2022.
Advised on convertible note financings in 2019 and 2020.
Advised on its Series A financing in 2021.
Advised on its investments in Renew Medical and EBR Systems.
Advised on various VC investments.
Convertible note investment in HealthEngine in 2022.
Advised Simplify Medical on its acquisition by NuVasive, Inc. for US$150 million plus additional milestone payments in 2021.
Advised on infant formula joint venture with Bega Cheese.
Advised on redomicile to Bermuda via scheme of arrangement.
Acted for StraxCorp on merger with CurveBeam AI LLC (2022).
Advised on implementation of its management incentive plan.
Advice on equity incentive plans.
The ASX is likely to introduce a series of new measures in 2024 aimed at streamlining aspects of the IPO listing process, as outlined in a recent adviser briefing.
From 1 October, we expect to see significant changes in the way that companies offer equity to their Australian personnel. For many businesses, new rules in the Corporations Act significantly...
ASIC and ASX have both announced temporary changes to their respective regulatory regimes to facilitate capital raisings for listed entities in response to the economic impact of COVID-19.